BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 832200)

  • 1. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
    MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
    Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
    Storm FK; Sparks FC; Morton DL
    Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
    Moff SL; Corey GR; Gottfredsson M
    Clin Infect Dis; 1999 Dec; 29(6):1569-70. PubMed ID: 10585816
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer immunotherapy.
    Richman SP; Gutterman JU; Hersh EM
    Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis.
    Spitler LE; Wong P; Sagebiel R
    Arch Dermatol; 1978 Oct; 114(10):1501-4. PubMed ID: 718187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
    Falk RE; MacGregor AB; Landi S; Ambus U; Langer B
    Surg Gynecol Obstet; 1976 Mar; 142(3):363-8. PubMed ID: 1251316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cromolyn prevents bronchospastic attacks caused by Bacillus Calmette Geurin immunotherapy for malignant melanoma patient.
    Wishnitzer R; Eliraz A; Fink A
    Ann Allergy; 1985 Aug; 55(2):167-9. PubMed ID: 3927789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.